BeyondSpring Pharmaceuticals

BeyondSpring Pharmaceuticals has developed innovative immuno-oncology cancer therapies, with a robust pipeline stemming from internal development as well as collaboration with the University of Washington, utilizing a ubiquitination platform for de novo drug discovery. BeyondSpring Pharmaceuticals' lead asset, Plinabulin, is being evaluated in two global Phase 3 clinical trials as both a direct anticancer agent for non-small cell lung cancer (NSCLC) and for the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring boasts an experienced management team with years of experience bringing drugs to the global market.